• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapy and medication are ineffective. The individual approach to treatment could be the solution.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into customized micro-interventions that improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their feature predictors and uncover distinct features that are able to change mood over time.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 However, only half of people suffering from the disorder receive treatment1. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients who have the highest likelihood of responding to certain treatments.

A customized depression treatment plan can aid. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from specific treatments. They are using mobile phone sensors, a voice assistant with artificial intelligence as well as other digital tools. With two grants awarded totaling over $10 million, they will employ these technologies to identify the biological and behavioral factors that determine the response to antidepressant medication and psychotherapy.

So far, the majority of research into predictors of depression treatment effectiveness has centered on clinical and sociodemographic characteristics. These include demographics like gender, age, and education, as well as clinical aspects such as symptom severity, comorbidities and biological markers.

While many of these variables can be predicted from information available in medical records, very few studies have used longitudinal data to explore the causes of mood among individuals. Many studies do not take into consideration the fact that mood can differ significantly between individuals. Therefore, it is essential to develop methods that permit the recognition of individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behavior and emotions that are unique to each person.

The team also devised a machine-learning algorithm that can model dynamic predictors for each person's post stroke depression treatment (peck-coley.thoughtlanes.net) mood. The algorithm blends these individual characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was not strong (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely among individuals.

Predictors of Symptoms

Depression is among the world's leading causes of disability1 but is often untreated and not diagnosed. In addition, a lack of effective interventions and stigmatization associated with depression disorders hinder many from seeking treatment for manic depression.

To aid in the development of a personalized treatment, it is crucial to determine the predictors of symptoms. However, the current methods for predicting symptoms are based on the clinical interview, which is unreliable and only detects a tiny number of features that are associated with depression.2

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing antenatal depression treatment Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements. They also capture a wide variety of unique behaviors and activity patterns that are difficult to document with interviews.

The study included University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment depending on the severity of their depression. Patients who scored high on the CAT-DI scale of 35 or 65 were assigned online support with the help of a peer coach. those with a score of 75 were routed to in-person clinics for psychotherapy.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial characteristics. The questions asked included age, sex, and education, financial status, marital status, whether they were divorced or not, the frequency of suicidal ideas, intent or attempts, and how often they drank. Participants also scored their level of pregnancy depression treatment severity on a scale of 0-100 using the CAT-DI. The CAT-DI test was carried out every two weeks for participants who received online support and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are aimed at finding predictors, which can aid clinicians in identifying the most effective drugs to treat each individual. Pharmacogenetics, in particular, uncovers genetic variations that affect how the human body metabolizes drugs. This allows doctors select medications that will likely work best for every patient, minimizing time and effort spent on trial-and error treatments and avoiding any side negative effects.

Another promising approach is building models for prediction using multiple data sources, combining clinical information and neural imaging data. These models can then be used to identify the most appropriate combination of variables predictive of a particular outcome, like whether or not a medication will improve mood and symptoms. These models can be used to predict the patient's response to a treatment, which will help doctors maximize the effectiveness.

A new era of research uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables and increase predictive accuracy. These models have been demonstrated to be effective in predicting the outcome of holistic treatment for anxiety and depression like the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the standard of future clinical practice.

In addition to prediction models based on ML The study of the mechanisms that cause depression is continuing. Recent findings suggest that depression is linked to the malfunctions of certain neural networks. This suggests that individual depression treatment will be built around targeted treatments that target these neural circuits to restore normal functioning.

One method to achieve this is to use internet-based interventions that can provide a more personalized and customized experience for patients. A study showed that a web-based program improved symptoms and improved quality of life for MDD patients. In addition, a controlled randomized study of a personalised treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a large proportion of participants.

Predictors of Side Effects

A major obstacle in individualized depression treatment is predicting which antidepressant medications will have the least amount of side effects or none at all. Many patients are prescribed various drugs before they find a drug that is safe and effective. Pharmacogenetics offers a new and exciting way to select antidepressant medications that is more efficient and targeted.

There are several variables that can be used to determine the antidepressant that should be prescribed, including gene variations, phenotypes of patients such as gender or ethnicity, and comorbidities. However it is difficult to determine the most reliable and accurate predictors for a particular treatment is likely to require controlled, randomized trials with significantly larger numbers of participants than those that are typically part of clinical trials. This is because it may be more difficult to determine moderators or interactions in trials that comprise only one episode per person instead of multiple episodes spread over a period of time.

Additionally, the prediction of a patient's reaction to a particular medication will likely also require information on comorbidities and symptom profiles, and the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Currently, only a few easily measurable sociodemographic variables as well as clinical variables appear to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

There are many challenges to overcome when it comes to the use of pharmacogenetics to treat depression. First, it is important to have a clear understanding and definition of the genetic factors that cause depression, as well as a clear definition of an accurate indicator of the response to treatment. Ethics, such as privacy, and the responsible use genetic information must also be considered. Pharmacogenetics could be able to, over the long term, reduce stigma surrounding treatments for mental illness and improve the outcomes of treatment. As with all psychiatric approaches it is essential to take your time and carefully implement the plan. The best option is to offer patients an array of effective medications for depression and encourage them to speak freely with their doctors about their experiences and concerns.